Tirzepatide: the dual-action drug rewriting the rules of metabolic medicine
It targets two hormones at once — and the results are unlike anything seen before in obesity medicine.
Tirzepatide: the dual-action drug rewriting the rules of metabolic medicine
It targets two hormones at once — and the results are unlike anything seen before in obesity medicine.
pru
THE PRU BRIEF
SCIENCE & WELLBEING
ISSUE NO. 09
Tirzepatide: the dual-action drug rewriting the rules of metabolic medicine
It targets two hormones at once — and the results are unlike anything seen before in obesity medicine.
Dear Pru Community,
Last issue we went deep on semaglutide — the GLP-1 agonist that changed the conversation around metabolic health and set a new benchmark for what weight management medicine could achieve. This issue is about the compound that raised that benchmark again.
Tirzepatide is the active ingredient in Mounjaro and Zepbound. On the surface it looks like another injectable weekly medication in the same class as semaglutide. But the mechanism is meaningfully different — and that difference matters both for understanding what it does and for knowing who it's most likely to help. The short version: tirzepatide activates two receptors instead of one, and the clinical data it has produced is, by the numbers, the strongest ever recorded for a weight management medication.
What tirzepatide actually is
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a single synthetic molecule engineered to activate two distinct hormone receptors simultaneously. GLP-1 (glucagon-like peptide-1) you already know from Issue 08. GIP is glucose-dependent insulinotropic polypeptide, a second gut hormone with its own role in insulin secretion, fat storage, and energy metabolism. Both are released naturally after eating. Tirzepatide mimics both at once.
The molecule was built around a 39-amino-acid GIP analogue as its backbone, with GLP-1 receptor activity incorporated into the same structure. A fatty acid chain — similar in concept to the one used in semaglutide — enables once-weekly dosing by binding to albumin in the bloodstream and extending the half-life to approximately five days. The result is a molecule that is structurally distinct from every previous GLP-1 drug, activating the two most important post-meal hormonal axes in a coordinated, simultaneous way.
ONE MOLECULE, TWO RECEPTORS
Why two receptors change everything
GIP was long considered the less interesting of the two incretins — the hormones released by your gut after a meal to coordinate the body's metabolic response. For years, GIP was even studied as a potential target for blocking, not activating, because elevated GIP was observed in obese individuals and researchers initially wondered if it was contributing to fat storage. Tirzepatide upended that thinking entirely.
What researchers found when GIP and GLP-1 receptors were activated together is that the combined effect on appetite, insulin sensitivity, and fat metabolism is greater than the sum of the two parts. GIP receptor activation in fat tissue appears to reduce the capacity of fat cells to store energy, while also amplifying the brain's response to GLP-1 — making the satiety signal stronger and more sustained. The two pathways don't just add up; they appear to potentiate each other.
The practical result is a compound with a deeper effect on the hypothalamic circuits that regulate hunger and body weight — what researchers sometimes call the body's defended weight set point. Where GLP-1 agonists like semaglutide override that set point through one hormonal signal, tirzepatide appears to reset it more fundamentally through two simultaneous signals working in concert.
What the clinical evidence actually shows
The SURMOUNT trial program is tirzepatide's equivalent of the STEP trials — large, rigorous, randomized controlled trials designed to establish its safety and efficacy profile. The headline numbers from SURMOUNT-1, published in The New England Journal of Medicine in 2022, were genuinely striking. At the highest dose of 15mg weekly, participants lost an average of 22.5% of body weight over 72 weeks. More than one-third lost 25% or more. These are figures that, until recently, were only associated with bariatric surgery.
Head-to-head comparisons with semaglutide have added important clinical context. The SURPASS-6 trial and later the SURMOUNT-5 trial directly compared tirzepatide against semaglutide 2.4mg in people with obesity. Tirzepatide produced significantly greater weight loss at every dose tested — approximately 47% more weight lost at comparable dose levels. Both drugs work. Tirzepatide, in most patients, works more.
Beyond weight, the metabolic improvements have been substantial. In people with type 2 diabetes, tirzepatide reduced HbA1c — the standard long-term measure of blood sugar control — more than any other medication in its class. A significant proportion of trial participants achieved HbA1c levels below the diagnostic threshold for diabetes entirely. Improvements in blood pressure, triglycerides, and liver fat have also been consistently observed across the trial program.
22.5%
average body weight lost at 15mg dose (SURMOUNT-1, 72 weeks)
~47%
more weight lost vs. semaglutide 2.4mg in head-to-head trials
>33%
of participants lost 25% or more of body weight at highest dose
Side effects: familiar territory, with some distinctions
The side effect profile of tirzepatide is similar to semaglutide in its broad outlines: nausea, vomiting, diarrhea, and constipation are the most commonly reported, driven by the same gastric emptying mechanism. These are most pronounced during dose escalation and tend to diminish as the body adjusts. Gradual titration — starting at 2.5mg and increasing slowly over several months — is the standard approach and makes a meaningful difference in tolerability for most people.
The muscle mass question deserves the same attention here as it does with semaglutide. Large weight loss from any cause involves some loss of lean tissue, and tirzepatide is no exception. What's notable is that some early data suggests the ratio of fat loss to lean mass loss may be somewhat more favorable with tirzepatide than with semaglutide — possibly because GIP receptor activation has distinct effects on adipose tissue — but this requires larger dedicated studies to confirm. Resistance training and adequate protein intake remain essential regardless.
Tirzepatide carries the same class-level boxed warning as semaglutide regarding thyroid C-cell tumors observed in rodent studies, and the same contraindications apply: a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. As with semaglutide, these tumors have not been observed in human clinical trials. Pancreatitis has been reported rarely and warrants monitoring, particularly in individuals with a prior history.
The research frontier: cardiovascular, liver, and kidney disease
The cardiovascular outcomes trial for tirzepatide — SURPASS-CVOT — is currently underway and its results are highly anticipated. Given the cardiovascular benefit demonstrated by semaglutide in SELECT, and the superior metabolic effects of tirzepatide, there is reasonable scientific basis for expecting meaningful cardiovascular protection. We don't have the final data yet, and it would be premature to assume equivalence, but the hypothesis is well-grounded.
What is already established is tirzepatide's effect on metabolic-associated steatotic liver disease (MASLD, formerly NASH) — a condition where fat accumulates in the liver and drives progressive damage. The SYNERGY-NASH trial, published in The New England Journal of Medicine in 2024, showed that tirzepatide led to resolution of NASH in 62% of participants versus 10% in the placebo group. This is the most substantial result ever recorded for a non-surgical liver disease intervention, and it has genuinely shifted how hepatologists think about the condition's treatment.
Kidney disease is another area of active investigation. Obesity-related kidney damage affects tens of millions of Americans and has historically been difficult to slow. Early trial data suggests tirzepatide reduces markers of kidney stress, and a dedicated renal outcomes trial is now enrolling. As with semaglutide, the picture emerging is of a molecule whose effects extend well beyond the number on the scale.
WORTH READING
Jastreboff, A.M. et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, pp. 205–216. (The SURMOUNT-1 trial.)
Loomba, R. et al. (2024). Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine, 391, pp. 299–310. (The SYNERGY-NASH trial.)
Tirzepatide at Pru: the same standard, a different tool
Tirzepatide and semaglutide are not interchangeable — they are distinct compounds with distinct mechanisms, and the right choice between them depends on your health history, metabolic goals, and how your body responds. That is exactly the kind of decision that belongs in a conversation with a licensed clinician, not an algorithm or a quiz. At Pru, every protocol starts there.
Whether your provider recommends tirzepatide or another compound, the infrastructure around it is the same: licensed American compounding pharmacies operating under strict federal quality standards, pharmaceutical-grade medication tested for purity and potency at every batch, and ongoing clinical oversight that doesn't end when the prescription ships. You hear from your provider. Your dose is reviewed. Your labs are monitored. This is what medically supervised therapy actually means.
The data on tirzepatide is genuinely exciting — the SURMOUNT results represent a step change in what's achievable without surgery. But the data also makes clear that medication alone is not the full picture. Body composition, protein intake, resistance training, and long-term sustainability are part of every protocol we design. Pru exists to give you access to the best tools available, and to help you use them well.
This newsletter is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Tirzepatide requires a prescription and must be evaluated for individual suitability by a licensed clinician. Always consult your provider before starting, adjusting, or stopping any medication.